Skip to content
Subscriber Only
Technology
Prognosis

FDA Moving at ‘Lightning Speed’ on Gilead Drug, Commissioner Says

  • Commissioner Hahn says agency wants to see totality of data
  • Several different pathways available for review, Hahn says
Video player cover image
Fauci Says Gilead Data Shows Covid-19 Drug Has 'Clear-Cut' Positive Effect
Updated on

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

The Food and Drug Administration is moving at “lightning speed” to review data on Gilead Sciences Inc.’s experimental Covid-19 treatment remdesivir, Commissioner Stephen Hahn said, after encouraging results emerged from a key U.S. trial.